Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
Antoine Lafuma1, John F Salmon2, Julien Robert1, Gilles Berdeaux31Cemka, Bourg-la-Reine, France; 2Oxford Eye Hospital, Oxford, UK; 3Conservatoire National des Arts et Métiers, Chaire Economie et Gestion des Services de Santé, Paris, FranceObjective: To compare treatment...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2011
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/315a710ed4e14123a2e0ed956083aceb |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:315a710ed4e14123a2e0ed956083aceb |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:315a710ed4e14123a2e0ed956083aceb2021-12-02T02:11:08ZTreatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database1177-54671177-5483https://doaj.org/article/315a710ed4e14123a2e0ed956083aceb2011-03-01T00:00:00Zhttp://www.dovepress.com/treatment-persistence-and-cost-effectiveness-of-latanoprostlatanoprost-a6661https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Antoine Lafuma1, John F Salmon2, Julien Robert1, Gilles Berdeaux31Cemka, Bourg-la-Reine, France; 2Oxford Eye Hospital, Oxford, UK; 3Conservatoire National des Arts et Métiers, Chaire Economie et Gestion des Services de Santé, Paris, FranceObjective: To compare treatment persistence and costs with 3 glaucoma treatment sequences (first-line/second-line): latanoprost/latanoprost–timolol (LLT), bimatoprost/bimatoprost–timolol (BBT), and travoprost/travoprost–timolol (TTT), derived from the UK General Practitioner Research Database (UK-GPRD).Methods: Patient records referring to ocular hypertension, topical glaucoma treatment, surgery, or laser therapy were extracted. Patients prescribed LLT, BBT, or TTT sequences were selected. Treatment failure was inferred from glaucoma prescription change (adding or removing a topical treatment, surgery, or laser therapy). Treatment durations preceding failure were compared by applying Wilcoxon’s test to survival curves. Adjustment on confounding variables was performed with a Cox model and a propensity score method. Unit costs were estimated from a UK National Health Service perspective.Results: A total of 1592 patients received LLT, 110 BBT, and 114 TTT. Their mean age was 68 years and the sex ratio almost 1 male:1 female. No significant demographic or comorbidity differences were observed between treatment sequences. Treatment persistence at 36 months was achieved in 60.0% of LLT, 55.5% of BBT, and 70.3% of TTT patients (P = 0.005). Resources consumed and associated monthly costs were significantly less for the TTT group (£17.74) compared with BBT (£21.30) and LLT (£22.37) groups.Conclusion: Analysis of data obtained from the UK-GPRD suggests that the TTT treatment sequence achieved longer treatment persistence at lower cost than LLT and BBT.Keywords: glaucoma, travoprost, timolol, latanoprost, bimatoprost, persistency, costs Antoine LafumaJohn F SalmonJulien Robertet alDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2011, Iss default, Pp 361-367 (2011) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Ophthalmology RE1-994 |
| spellingShingle |
Ophthalmology RE1-994 Antoine Lafuma John F Salmon Julien Robert et al Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database |
| description |
Antoine Lafuma1, John F Salmon2, Julien Robert1, Gilles Berdeaux31Cemka, Bourg-la-Reine, France; 2Oxford Eye Hospital, Oxford, UK; 3Conservatoire National des Arts et Métiers, Chaire Economie et Gestion des Services de Santé, Paris, FranceObjective: To compare treatment persistence and costs with 3 glaucoma treatment sequences (first-line/second-line): latanoprost/latanoprost–timolol (LLT), bimatoprost/bimatoprost–timolol (BBT), and travoprost/travoprost–timolol (TTT), derived from the UK General Practitioner Research Database (UK-GPRD).Methods: Patient records referring to ocular hypertension, topical glaucoma treatment, surgery, or laser therapy were extracted. Patients prescribed LLT, BBT, or TTT sequences were selected. Treatment failure was inferred from glaucoma prescription change (adding or removing a topical treatment, surgery, or laser therapy). Treatment durations preceding failure were compared by applying Wilcoxon’s test to survival curves. Adjustment on confounding variables was performed with a Cox model and a propensity score method. Unit costs were estimated from a UK National Health Service perspective.Results: A total of 1592 patients received LLT, 110 BBT, and 114 TTT. Their mean age was 68 years and the sex ratio almost 1 male:1 female. No significant demographic or comorbidity differences were observed between treatment sequences. Treatment persistence at 36 months was achieved in 60.0% of LLT, 55.5% of BBT, and 70.3% of TTT patients (P = 0.005). Resources consumed and associated monthly costs were significantly less for the TTT group (£17.74) compared with BBT (£21.30) and LLT (£22.37) groups.Conclusion: Analysis of data obtained from the UK-GPRD suggests that the TTT treatment sequence achieved longer treatment persistence at lower cost than LLT and BBT.Keywords: glaucoma, travoprost, timolol, latanoprost, bimatoprost, persistency, costs |
| format |
article |
| author |
Antoine Lafuma John F Salmon Julien Robert et al |
| author_facet |
Antoine Lafuma John F Salmon Julien Robert et al |
| author_sort |
Antoine Lafuma |
| title |
Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database |
| title_short |
Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database |
| title_full |
Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database |
| title_fullStr |
Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database |
| title_full_unstemmed |
Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database |
| title_sort |
treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the united kingdom general practitioner research database |
| publisher |
Dove Medical Press |
| publishDate |
2011 |
| url |
https://doaj.org/article/315a710ed4e14123a2e0ed956083aceb |
| work_keys_str_mv |
AT antoinelafuma treatmentpersistenceandcosteffectivenessoflatanoprostlatanoprostampndashtimololbimatoprostbimatoprostampndashtimololandtravoprosttravoprostampndashtimololinglaucomaananalysisbasedontheunitedkingdomgeneralpractitionerresearchdatabase AT johnfsalmon treatmentpersistenceandcosteffectivenessoflatanoprostlatanoprostampndashtimololbimatoprostbimatoprostampndashtimololandtravoprosttravoprostampndashtimololinglaucomaananalysisbasedontheunitedkingdomgeneralpractitionerresearchdatabase AT julienrobert treatmentpersistenceandcosteffectivenessoflatanoprostlatanoprostampndashtimololbimatoprostbimatoprostampndashtimololandtravoprosttravoprostampndashtimololinglaucomaananalysisbasedontheunitedkingdomgeneralpractitionerresearchdatabase AT etal treatmentpersistenceandcosteffectivenessoflatanoprostlatanoprostampndashtimololbimatoprostbimatoprostampndashtimololandtravoprosttravoprostampndashtimololinglaucomaananalysisbasedontheunitedkingdomgeneralpractitionerresearchdatabase |
| _version_ |
1718402639333425152 |